Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum -a systematic review of the evidence from randomized trials

Purpose: To evaluate the chemotherapeutic options for women with recurrent epithelial ovarian cancer who have received platinum-based chemotherapy.

Methods: A systematic search of the Medline, CancerLit and Cochrane Library databases was performed for the period from 1984 to June 2001 to find randomized trials comparing second- or higher-line chemotherapy regimens in patients with recurrent platinum-pretreated epithelial ovarian cancer.

Results: Seven randomized trials have failed to demonstrate the clear superiority of any one chemotherapy regimen in terms of improvements in long-term survival, quality of life or response rate. One trial detected a statistically significant difference between treatments in progression-free survival, which was longer with cyclophosphamide/doxorubicin/cisplatin than with paclitaxel in women with platinum-sensitive ovarian cancer. Another trial did not show a difference between liposomal doxorubicin and topotecan overall in women with recurrent ovarian cancer but a subgroup analysis detected a significant survival advantage for liposomal doxorubicin over topotecan in women with platinum-sensitive disease.

Conclusion: The evidence available does not support firm conclusions about the preferred chemotherapy regimen for recurrent ovarian cancer. Randomized trials that compare new drugs with current standard treatments are needed.

Ovarian cancer, Recurrent, Chemotherapy, Platinum

[1] National Cancer Institute of Canada: Canadian Cancer Statistics 2001, Toronto, Canada, 2001.

[2] McGuire W. P., Ozols R. F.: "Chemotherapy of advanced ovarian cancer". Se min. Oneal. I 998, 25 (3), 340.

[3] Ozols R. F. "Treatment of recurrent ovarian cancer: Increasmg options - "recurrent" results [editorial].": J Clin. Oneal. 1997, 15 (6), 2177.

[4] Patnaik A. Doyle C, Oza A. M.: "Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost". Anti-Cancer Drugs 1998, 9 (10), 869.

[5] Slevin M. L., Stubbs L, Plant H.J., Wilson P, Gregory W. M., Armes P. J. et al.: "Attitudes to chemotherapy: comparing views of doctors, nurse、, and general public". 81: Med. J., 1990, 300 (6737), 1458.

[6] du Bois A., Luck H. J., Meerpohl H. G.: "Treatment for recurrent or progressive ovarian cancer failing first-line chemotherapy: a review of systemic treatment modalities". Zentralhl. Gynakol., 1997, 119 (7), 299.

[7] Gore M. E.,F ryatt I.,W ilthsaw E.,D awson T:.'Treatment of relapsed carcinoma of the ovary with cisplatin or(..arboplatin following initial treatment with these compounds''. Gynecol. Oncol., 1990. 36 (2). 207.

[8] Markman M.,B lessingJ .,A lvarez R. D.,H anjani P.,W aggoner S., Hall K.: "Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a gynecologic oncology group study". Gynecol. Oncol., 2000, 77 (1).112.

[9] McGuire W. P., Blessing J. A., Bookman M. A., Lentz S., Dunton C. J.: "Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a gynecologic oncology group study''. J. Clin. Oncol., 2000, 18 (5).1062.

[10] Bustova I., Blaha 0., Brychta M., Janousek M..Kalabova R., Hanus L., et al.:'Topotecan in the treatment of advanced recurrent epithelial ovarian cancer [abstract]". Proc. Am. Soc. Clin Oneal., 2000, 19, 397a.

[11] Kaufmann M., von Minckwitz G. "Gemcitabme tn ovanan cancer an overview of safety and efficacy". Eur .J. Cancer, 1997, 33(Suppl. I),S 31.

[12] Coenen M., Berteloot P., Amant F., Vangramberen M., Vergote I ''Gemcitabine in platin-paclitaxel resistant ovarian carcinoma [abstract]". Proc. Am. Soc. Clin. Oneal., 2000, 19, 405a.

[13] von Minckwitz G., Bauknecht T., Yissern-Grul C. M., Neijt J. P.: ''Phase II study of gemcitabine in ovarian cancer". Ann. Oncol. 1999, 10 (7), 853.

[14] Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M. et al.: "Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation". J. Clin. Oncol., 1997, 15(3). 987.

[15] Medi-View Expre、s Report.:'The promise of targeted novel chemotherapy in solid tumors". Proceedings of the 10th Biennial European Cancer Conference (ECCO IO), 1999 Sept 12-16, Vienna, Austria.

[16] Gordon A. N., Granai C. 0., Rose P. G., Hainsworth J., Lopez A., Weissman C. et al.: "Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer". J. Clin. Oneal., 2000; 18 (17), 3093.

[17] Eisenhauer E., ten Bokkel Huinink W. W., Swenerton K. D.. Gianni L., Myles J., van der Burg M. E. et al.: "European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion". J Clin. Oncol., 1994, 12 (12), 2654.

[18] Hoskins P., Eisenhauer E., Beare S.. Roy M., Drouin P., Stuart G et al.: ·'Randomized phase TT study of two schedules on topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study". J. Clill Oncol., 1998, 16 (6), 2233.

[19] Sugiyama T.,N is加da T.,O okura N.,Y akushiji M.,I keda M..N odaK et al.: "Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer') [abstract]". Proc. Am. Soc. Clin. Oncol.. 1997, 16, 378a.

[20] Bolis G.. Scarfone G.. Giadina G., Villa A., Mangili G.,Melpigano M et al.: rboplatin alone vs carboplatin plus epidoxorubicin as second-line chemotherapy for cisplatin- or carboplatinsensitive ovarian cancer". Gynecol. Oncol., 2001, 81 (1), 3.

[21] Colombo M., Marzola M., Parma G., Cantu M. G., Tarantino G., Fornara G et al.: "Paclitaxel vs cap (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase TT study [abstract]". Proc. Am. Soc. Clin. Oncol.. 1996, 15, 279.

[22] ten Bokkel Huinink B. W., Gore M., Carmichael J., Gordon A.. Malfetano J.. Hudson I et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oncol., 1997, 15 (6). 2183.

[23] Gordon A.,C armichaelJ ..M alfetano M.,G ore M.,S paczynski M., Clarke-Pearson D et al.:.. Final analysis of a phase III study of topotecan vs paclitaxel in advanced epithelial ovarian carcinoma [abstract]". Proc. Am. Soc. Clin. Oncol., 1998, 17, 356a.

[24] Piccart M.J .,G reenJ . A.,L acave A.J .,R eed N..Y ergote I..B enedetti- Pancini P. et al.: "Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase TT study of the European Organization for Research and Treatment of Cancer Gynecology Group". J. C/in. Oncol..2 000,1 8 (6),1193.

[25] Gordon A. N., Fleagle J. T.. Guthrie D., Parkin D. E.. Gore M. E., Lacave A.J .:''Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J. Clin. Oneal., 2001, 19 (14), 3312.

[26] Bolis G., Parazzini F., Scarfone G., Villa A., Amoroso M.. Rabaiotti E. et al.: "Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer". Gynecol. Oneal., 1999, 72 (1), 60.

[27] Torri V., Floriani I., Tinazzi A., Conte P. F., Ravaioli A., Maria Cantu G. et al.: "Randomized trial comparing paclitaxel+doxorubicin versus paclitaxel as second line therapy for advanced ovarian cancer patients in early progression after platinum based chemotherapy [abstract]". Proc. Am. Soc. Clin. Oncol., 2000,19, 381a.

[28] Geels P., Eisenhauer E.. Bezjak A. N., Zee B., Day A.: "The palliative effect of chemotherapy: objective tumor response correlates with symptom improvement in patients with metastatic breast cancer··. J. Clin Oncol., 2000, 18 (12), 2395.

[29] Markman M.. Rothman R., Hakes T.. Reichman B., Hoskins W., Rubin S.. Jones: "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oncol., 1991, 9 (3), 389.

[30] Bookman M. A.: "Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy". Oncologist, 1999, 4 (2), 87.

[31] Blackledge G., Lawton F., Redman C., Kelly K.: "Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and design of phase II trials". Br. J. Cancer, 1989, 59 (4), 650.

[32] Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A. et al.: "Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer". J. Clin. Oncol., 1995, 13 (7), 1584.